General Medicines Growth: 7% for the quarter. Vaccines Sales Decline: 15% for the quarter due to lower sales of Arexvy and Shingrix. Core Operating Profit Growth: 5% excluding COVID. Core EPS Growth: ...

Big pharma has long been a force for commercial broadcasters. Promotions for GSK’s respiratory vaccine Arexvy and its blockbuster shingles shot Shingrix are a big presence. But despite all the ...

An Oct. 24 Instagram post (direct link, archive link) shows Fox News White House correspondent Peter Doocy questioning White House press secretary Karine Jean-Pierre about disaster relief related ...

Total vaccine sales were down due to lower sales of Arexvy and Shingrix ... We have a strong balance sheet, which provides optionality to accelerate further growth organically and through business ...

“We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted Arexvy, indicating our potential best-in-class ...

The U.K. firm, whose vaccines include Arexvy and Shingrix, now expects 2024 vaccine sales to decrease by a low-single digit percentage. GSK's (GSK) shares are falling 4% in premarket trading ...

The Arexvy development is disappointing for GSK ... Despite this, the shares are still trading at a steep discount to peers. In fact, the forward price-to-earnings multiple for 2025 is just ...

However, sales across critical divisions were lackluster, with key products such as the respiratory syncytial virus (RSV) vaccine, Arexvy, missing expectations by 21%, and Shingrix sales falling ...

Vaccine sales performance was primarily impacted by lower sales of Arexvy with changes in Advisory Committee on Immunization Practices (ACIP) guidelines, prioritization of COVID-19 vaccinations in ...

For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and delayed ...